| 8.03 Data as of May 24 |  0.00 / 0.00%Today’s Change | 1.55 Today|||52-Week Range 9.98 | +206.49% Year-to-Date |
| Why Keryx is Lagging But Acadia is Zooming (Hint: It's About NCE) May 21 / TheStreet.com | Rockwell Medical Run-Up Trade Follows Financing May 21 / TheStreet.com |
| Previous close | 8.03 |
| Today’s open | 7.99 |
| Day’s range | 7.96 - 8.09 |
| Volume | 1,037,370 |
| Average volume (3 months) | 2,855,879 |
| Market cap | $656.2M |
| Dividend yield | -- |
| Earnings growth (last year) | +15.71% |
| Earnings growth (this year) | +4.02% |
| Earnings growth (next 5 years) | +30.00% |
| Revenue growth (last year) | -100.00% |
| P/E ratio | NM |
| Price/Sales | -- |
| Price/Book | 55.03 |
| Today’s change | Today’s % change | |
|---|---|---|
| IDIXIdenix Pharmaceutica... | +0.12 | +2.86% |
| NXTMNxstage Medical Inc | +0.27 | +1.99% |
| SGYPSynergy Pharmaceutic... | +0.05 | +0.98% |
| BRLIBio-Reference Labora... | -0.46 | -1.47% |
| Next reporting date | August 12, 2013 |
| EPS forecast (this quarter) | -$0.10 |
| Annual revenue (last year) | $0.00 |
| Annual profit (last year) | -$25.4M |
| Net profit margin | -- |
Sector Health Technology |
Industry Biotechnology |
Chief Executive Officer & Director Ronald Bentsur, MBA |
Chief Financial Officer, Secretary & Treasurer James F. Oliviero, III, CFA |
Corporate headquarters New York, New York |
.
